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In a model of growth restricted sheep pregnancy, we previously demonstrated that transient 
uterine artery VEGF overexpression can improve fetal growth. We tested this approach in 
guinea pig pregnancies, where placental physiology is more similar to human. 
Method: Fetal growth restriction (FGR) has been obtained through peri-conceptual nutrient 
restriction in virgin guinea pigs. Ad.VEGF-A165 or Ad.LacZ (1x10
10
vp) were applied at mid-
gestation in laparotomy, delivered externally to the uterine circulation via thermosensitive 
gel. At short-term (3-8 days post-surgery) or at term gestation, pups have been weighed and 
tissues sampled for vector spread analysis, VEGF expression and its downstream effects. 
Results:  
Fetal weight at term was increased (88.01±13.36g, n=26) in Ad.VEGF-A165-treated animals, 
compared to Ad.LacZ treatment (85.52±13.00g, n=19, p=0.028).  Brain, liver, lung weight 
and crown rump length were significantly larger in short-term analyses, as well as VEGF 
expression in transduced tissues. At term, molecular analyses confirmed the presence of 
VEGF transgene in target tissues, but not in fetal samples. Tissue histology analysis and 
blood biochemistry/haematological examination were comparable with controls. Uterine 
artery relaxation in Ad.VEGF-A165-treated dams was higher compared to Ad.LacZ-treated 
dams. 
Conclusions: Maternal uterine artery Ad.VEGF-A165 increases fetal growth velocity and 




























































































































































































































































































































































































Fetal growth restriction (FGR), where a fetus fails to achieve its genetic growth potential, 
affects up to 8% of all pregnancies and is a leading cause of perinatal death (1). Affected 
fetuses are also at increased risk for neonatal death, birth asphyxia and major long term 
morbidity (1).  There is currently no treatment (2). Even for normally grown fetuses born 
very premature, small increases in fetal growth and gestation at birth are associated with 
major improvements in survival and morbidity (3,4). Therapeutic interventions for severe 
FGR might therefore be successful by improving outcome if they lead to even small increases 
in fetal growth, or later gestation at delivery.  
More than half of FGR occurs secondary to placental insufficiency, which is characterized by 
reduced uterine blood flow (UBF). During pregnancy UBF increases tremendously as a result 
of increased maternal cardiac output, increased uterine artery diameter and trophoblast driven 
modification of the uterine spiral arteries (5)(6). Reducing UBF is known to cause FGR in 
animals such as the pregnant rat, guinea pig or sheep, emphasizing that fetal growth is 
dependent on UBF (7).   
We have explored the therapeutic use of vascular endothelial growth factor (VEGF), a potent 
vascular endothelial cell mitogen, with powerful vasodilatory and pro-angioenic effects. 
These are mediated in part through the ability of VEGF to stimulate endothelial production of 
nitric oxide and prostacyclin via its major signalling receptor KDR (VEGF Receptor 2) (8). 
VEGF plays an important role in uteroplacental development, angiogenesis and blood flow, 
and in FGR, maternal serum levels of VEGF are significantly lower than in normal 
pregnancy (9)(10). We have developed a targeted approach using an adenovirus vector (Ad) 
to transiently over-express VEGF locally in the uteroplacental circulation. We have 
demonstrated that this increases UBF (11)(12)(13) and is associated with improved fetal 
growth velocity in a sheep paradigm of FGR (14). The placental physiology of sheep differs 






















































































































































































































































































































































































substantially from humans (7). We selected the guinea pig for this study for a variety of 
reasons including its haemomonochorial placentation, that which is most similar to third 
trimester human placentation (15), homologous process of trophoblast invasion (15) and 
trophoblast cell proliferation (16), and a longer gestation than other rodents, making it thus 
more suited for therapeutic evaluation (7).  Finally, periconceptual nutrient deprivation in the 
guinea pig impairs placental functional development, reduces the placental exchange and 
trophoblastic surface, increases the thickness of the exchange barrier and causes a 40% 
reduction in fetal weight with brain sparing (17)(18). Ad.VEGF-A165 induced reversal of 
FGR in this model, where there is a general impairment of placental function, would make 
these studies relevant to human FGR where the lesion is rarely simply due to reduced UBF. 
The primary aim of our study was to determine the effect of short term overexpression of 
VEGF-A165 applied locally to the uteroplacental site on fetal growth velocity and weight at 


























































































































































































































































































































































































Materials and Methods 
Animals 
To induce FGR, female virgin Dunkin Hartley guinea pigs received 70% normal nutrient 
intake for 4 weeks before time-mating (18).  Pregnancy was confirmed using ultrasound (18). 
70% nutrient restriction was continued until day 35 of gestation, when it was increased to 
90% until term at 60-65 days. Dams were given unlimited access to food during recovery 
from surgery.  All procedures on animals were conducted in accordance with UK Home 
Office regulations and the Guidance for the Operation of Animals (Scientific Procedures) Act 
(1986), under Home Office Project Licence. 
Animal surgery and vector injection 
At mid-gestation (range 29-39 gestational days), under a general anaesthetic (ketamine, 
44mg/kg and xylazine, 5 mg/kg IM, maintained by isoflurane inhalation, 1.5-2.0%) fetal 
measurements were taken (18) and a laparotomy was performed. Vector (1x10
10
 particles per 
animal), either control (Ad.LacZ) or treatment (Ad.VEGF-A165), suspended in freshly made 
thermosensitive gel (F-127, Sigma) was applied under direct vision to exposed uterine and 
radial arteries supplying both uterine horns as described (19). Dams were randomly assigned 
to VEGF or control vector and subsequent analyses were performed blinded to study group 
assignation. After a short period (3-8 days), or at term (60-64 gestational days), animals were 
killed for post mortem examination. Maternal and fetal measurements were recorded using 
electronic callipers (biparietal diameter (BPD), occipital snout length (OSL), crown rump 
length (CRL), femur length (FL)) and measuring tape (abdominal circumference (AC)), and 
tissues were extensively sampled. Fresh tissues were flash frozen in liquid nitrogen and 
stored at -80°C.  Tissue for histological and immunohistochemical studies were fixed in 4% 
paraformaldehyde before being embedded in paraffin wax. 























































































































































































































































































































































































Quantitative determination of VEGF protein expression in uterine arteries (UtAs), radial 
arteries (RAs) and serum was performed using ELISA, as recommended by the manufacturer 
(DVE00, R&D Systems, Abingdon, UK). Tissue samples were solubilized by 
homogenization in Radio ImmunoPrecipitation Assay (RIPA) Buffer (R0278, Sigma 
Aldrich). Protein content was determined using a Protein Assay Kit (500-0001, Bio-Rad,UK). 
Serum was assayed undiluted. 
Molecular analyses  
Ad.VEGF-A165 vector expression was assessed using semi-nested reverse transcription-PCR 
in maternal and fetal tissues, with method and target primers as described (12). Primers 
designed to amplify sequences within the guinea pig β-actin gene were used as a positive 
control (20). The reaction conditions for both rounds were initial denaturation at 94°C for 4 
min, followed by 30 cycles of denaturation at 94°C for 60 secs, annealing for 64°C for 60 sec 
and extension for 72°C for 60 secs, and a final extension period of 72°C for 10 mins.  PCR 
products were analysed on a 1.2% agarose gel using GelRed fluorescent nucleic acid gel 
stains (VWR). 
Biochemistry, haematology and histological analysis 
Blood was collected from dams and pups at necropsy. Standard small mammal biochemistry 
and haematology panels were performed by Royal Veterinary College Clinical Services 
Diagnostic Laboratories. Control blood was from ad libitum (ad lib) fed dams from the same 
animal colony. Stained hematoxylin & eosin (H&E) maternal, fetal and placental tissue 
sections were reviewed by an expert perinatal and placental pathologist who was blinded to 
experimental group. Trophoblast invasion was scored from zero (no invasion) to three 
(maximal invasion), in uterine and radial arteries. 






















































































































































































































































































































































































Intima to media ratios 
H&E stained sections of the uterine arteries were imaged using a digital slide scanner 
(Nanozoomer, Hamamatsu). The relative thicknesses of the intimal and medial layers were 
determined with NDP.view software and used to calculate the intima:media ratios. 
Immunohistochemistry  
To evaluate neovascularisation around the uterine and radial arteries, artery sections were 
immunostained with anti-von Willebrand factor (1:200, A0082, Dako) using an ABC kit 
(Vector Laboratories, Peterborough, UK); 3,30- diaminobenzidine (Sigma Aldrich, 
Gillingham, UK) and a hematoxylin counterstain. Slides were imaged as above and positively 
stained adventitial blood vessels were counted. To assess apoptosis and proliferation, 
placental sections were stained with anti-cleaved caspase 3 (1:800, 9664S, Cell Signalling) or 
anti-Ki-67(1:125, M724029-2, Dako) respectively. Stained placental sections were imaged 
using a digital slide scanner, as above. To obtain cell counts, each image was divided into six 
sections, and a field of view at 20x magnification randomly captured from each section.  
Total positive cells per field of view were counted in the ImageJ program (National Institutes 
of Health, USA) using the Cell Counter function. 
Western blot 
Protein extracts from the snap-frozen uterine artery (UtA) tissues were used to estimate 
eNOS, iNOS and phosph-eNOS levels by western blotting.  Tissue was lysed by sonication in 
RIPA buffer (R0278, Sigma, Dorset, UK) and the resulting lysates were analysed by SDS-
PAGE on 4-20%% Tris-glycine gels (Novex EC6025BOX, Invitrogen, Paisley, UK), 
followed by electrotransfer onto nitrocellulose membranes (LC2001, Invitrogen, Paisley, 
UK). Membranes were blocked with 5% (w/v) bovine serum albumin (BSA, A9418, Sigma, 
Dorset, UK) in phosphate-buffered saline (PBS-T) for 1 h at room temperature, before being 
probed with the primary antibody by overnight incubation at 4°C, followed by incubation for 






















































































































































































































































































































































































1 h at room temperature with a horseradish peroxidase (HRP)-linked secondary antibody 
(1:8000, Santa-Cruz Biotechnology) and detection using enhanced chemiluminescence (ECL) 
reagents (GE Healthcare, Little Chalfont, UK), following the manufacturer's protocol. 
Immunoblots were quantified by scanning of films with a calibration strip and analysis by 
densitometry using ImageJ (National Institutes of Health). The primary antibodies used were 
monoclonal mouse anti-eNOS/iNOS Type III antibody (1:3000, 610296, BD Transduction 
Laboratories, Oxford, UK), monoclonal mouse anti-iNOS/NOS Type II antibody (1:3000, 
610328, BD Transduction Laboratories , Oxford, UK) GAPDH was probed using a goat 
polyclonal, GAPDH antibody (V-18)-HRP conjugate (1:1000, 20357, Santa Cruz 
Biotechnology, Heidelberg, Germany). 
Myography 
Cleared uterine artery (UtA) segments 1-2 mm in length were mounted in a two-chambered 
wire myograph (410A, Danish Myotechnology, Aarhus, Denmark) run using Myodaq.2.vi 
software, and maintained according to standard protocols (21). Concentration response curves 
to phenylephrine (PE) and acetylcholine (ACh) were constructed for each vessel. 
Statistics 
Sample size calculations were based on the primary outcome of fetal birthweight, and a 
sample data set of birth weight data was obtained from 29 normal dams and 89 offspring. A 
Generalized Linear Mixed Models (GLMM) approach was used for statistical analysis as 
described (22), with dam and treatment (Ad.LacZ or Ad.VEGF-A165) set as a factor, with 
fetus sex, litter size and gestational age (gestational days) at post mortem as covariates. Fetus 
sex was found to have no effect and was removed as covariate.  GLMM statistical analysis 
was needed for our set of data as the model is predicting random effects in addition to the 
usual fixed effects, with non-normal data. Statistical significance was considered achieved if 
P<0.05, and p-values are reported. 























































































































































































































































































































































































Seven dams treated with Ad.LacZ delivered of 19 pups, and 8 dams treated with Ad.VEGF-
A165 delivered of 26 pups were included in the study.  A further 10 females underwent 
surgery but were excluded from the study (Supplementary Table 1). Eight of those dams had 
immediate postoperative surgical complications: four miscarried 1, 5 and 6 days post-surgery, 
two sustained leg wounds during operative handling and were culled, one died secondary to 
aspiration pneumonia and one developed an abdominal infection and was culled.  Two further 
animals were culled at later stages in consultation with veterinarians, one after exhibiting 
signs of distress and weight loss likely resulting from pregnancy toxaemia at day 5 
postoperatively, and one with a wound hernia at day 7 postoperatively. The average litter size 
was 2.7±1.7 for controls and 3.25±1.8 for Ad.VEGF-A165 animals.  There was no effect of 
treatment on litter size (p=0.50; 2 tailed T test).  
 
Fetal Measurements 
There was no significant difference between the groups in any fetal measurements taken at 
mid gestation by detailed fetal ultrasound before Ad vector treatment. Treatment with 
Ad.VEGF-A165 resulted in a significant increase in fetal weight at term (88.01±13.36g) 
compared to control Ad.LacZ treated fetuses (85.52±13.00g, p=0.028, Generalized Linear 
Mixed Models, Figure 1 and Table 1). There was no effect of treatment on placental weight 
or diameter, although placental depth was increased (Table 1a, Figure 1). Placental 
efficiency, as indicated by the placental/fetal weight ratio, was not significantly different 
(Table 1a). Other fetal growth measurements were significantly increased by Ad.VEGF-A165 
treatment (Table 1b), including brain, liver, lung weight and crown rump length (CRL). 
Kidney weight, heart weight and biparietal diameter (BPD) were not affected. Ad.VEGF-A165 
increased the fractional growth rate of the BPD and occipital snout length (OSL) head 






















































































































































































































































































































































































measurements and the brain to fetal weight ratio at term compared to Ad.LacZ treatment 
(Table 1b). Fractional growth rate of the abdominal circumference (AC), CRL, femur length 
(FL), placental diameter and thickness was not different between the groups (data not 
shown).  
 
VEGF protein expression 
VEGF expression following treatment with Ad.VEGF-A165 was confirmed by ELISA in 
collected samples. Protein was detected in maternal and fetal serum, with higher levels 
detected in fetal serum from dams treated with Ad.VEGF-A165 (maternal n=6, fetal n=5) than 
those treated with Ad.LacZ (maternal n=3, fetal n=4) (Figure 2a). VEGF protein was also 
detected in uterine artery samples (Ad.VEGF-A165 n=9 samples from 6 animals) but levels 
were not significantly higher compared to Ad.LacZ samples (n=3 samples from 6 animals, 
Figure 2b). Results were similar in the radial artery samples (Ad.VEGF-A165 n=7 samples 
from 6 animals, Ad.LacZ n=4 samples from 3 animals, Figure 2c).   
Immunohistochemical analysis for VEGF expression, also at 3-8 days post therapy, showed 
specific staining of VEGF around the target vessels in both the Ad.LacZ- and Ad.VEGF-
A165-treated animals, with a visible increase in Ad.VEGF-A165 treated uterine arteries (Figure 
3 a, d).  We found no detectable difference in VEGF receptor 1 or 2 expression in the uterine 
arteries of Ad.LacZ- and Ad.VEGF-A165-treated animals (Figure 3b, c, e, f). Overall 
immunohistochemical staining was more intense for all three proteins in radial arteries, with 
no clear difference between Ad.LacZ- and Ad.VEGF-A165-treated animals (data not shown). 
 
Vector spread 
RT-PCR analysis showed the presence of the transgene in the target uterine and radial arteries 
of three of four Ad.VEGF-A165 treated animals (Figure 4). All other tissues tested (Maternal: 






















































































































































































































































































































































































uterine arteries, radial arteries, uterus, lung, heart, ovary, liver, adrenal gland, kidney, spleen, 
brain, retina, thymus: and Fetal: placenta, membranes, umbilical cord, lung, thymus, heart, 
spleen, liver, gonads, adrenal gland, kidney, muscle, skin, brain and bone marrow) were 
negative, with the exception of one maternal ovary sample. 
 
Histological, haematological and biochemical evaluations  
A standard small mammal haematology panel returned similar values for all term maternal 
serum submitted (VEGF n=3, LacZ n=1, ad lib n=3), within the standard range for the panel 
(Pathology department, Royal Veterinary College, Hawkshead, UK) and comparable to 
published guinea pig values (23). Fetal values differed as expected from maternal values, but 
there were no differences between values from fetuses of ad lib (n=3 from 3 dams), 
Ad.VEGF-A165 (n= 7 from 4 dams) and Ad.LacZ (n=2 from 1 dam) subjects, with the 
exception of mean corpuscular volume (MCV), which was slightly elevated in the Ad.VEGF-
A165 treated fetuses (93.1±8.0fL) compared to Ad.LacZ treated and ad lib fetuses 
(82.0±6.8fL). In biochemistry tests, there were decreased levels of total protein and globulin 
and increased levels of potassium, compared with the standard ranges for small mammals and 
guinea pigs as before (23).  However, these differences were preserved across all groups 
(Ad.VEGF-A165 n=5, Ad.LacZ n=1, ad lib n=5). As with the haematology, there were no 
difference between values from fetuses of ad lib (n=4 from 4 dams), Ad.VEGF-A165 (n= 8 
from 5 dams) and Ad.LacZ (n=2 from 1 dam) subjects. 
Microscopic histological examination of dams (n=2 each group), fetuses (n=2 each group) 
and placentas (control n=6, Ad.VEGF-A165 n=7) did not reveal any pathological 
observations. The proportion of animals with moderate or maximum (scored 2 or 3) 
trophoblast invasion in the uterine spiral arteries did not differ between dams treated with 
Ad.VEGF-A165 (4 of 10 dams) and Ad.LacZ (2 of 6 dams, P=1.00, Fisher’s exact test). 






















































































































































































































































































































































































Neither was there a difference between treatment groups in the proportion of dams with 
moderate or maximal trophoblast invasion in the radial arteries (Ad.LacZ, 4 of 4 dams, 
Ad.VEGF-A165
 
, 3 of 5 dams, P=0.44, Fisher’s exact test). 
 
Mechanism of action 
Myography experiments on uterine artery (UtA) segments sampled at post mortem 
examination 38 days ±5 post vector application showed no change in the mean contractile 
response to phenylephrine in the Ad.VEGF-A165 (n=7) transduced vessels when compared 
with Ad.LacZ vessels (n=5) (Figure 5a).  Neither was there an overall change in the 
relaxation of vessels in response to acetylcholine as analysed by 2-way ANOVA with 





prior to saturation, there was significantly more relaxation, with Emax values 72.7±5.8 for 
Ad.VEGF-A165 vs. 50.5±3.5 for Ad.LacZ (p=0.050, two-way ANOVA). 
We observed no difference in intima/media ratios in uterine arteries between Ad.LacZ (n=7 
arteries from 4 animals) and Ad.VEGF-A165 (n=11 arteries from 6 animals) treated animals, 
measured on haematoxylin and eosin stained sections (data not shown).  The finding was the 
same in the radial arteries, where no differences between Ad.LacZ (n=24 arteries from 4 
animals) and Ad.VEGF-A165 (n=15 arteries from 4 animals) treated animals were seen (data 
not shown). 
We detected an increase in the levels of eNOS and iNOS between the Ad.LacZ (n=3) and 
Ad.VEGF-A165 (n=3) transduced uterine arteries by western blotting 3-8 days after gene 
transfer (Supplementary Figure 1). eNOS and iNOS expression was significantly higher in 
uterine arteries treated with Ad.VEGF-A165 compared to Ad.LacZ (eNOS: 1.58 ± 0.2 
(Ad.VEGFA165) vs. 0.69 ± 0.18 (Ad.LacZ), p<0.001; iNOS: 2.9 ± 0.59 (Ad.VEGFA165) vs. 
0.81 ± 0.1 (Ad.LacZ), p<0.001). 






















































































































































































































































































































































































Ad.VEGF-A165 transduction increased the average number of von Willebrand factor-stained 
adventitial blood vessels around the uterine arteries (77.5±38.6, n=12 arteries from 8 animals) 
compared with Ad.LacZ transduction (32.5±14.2, n=8 arteries from 5 animals, p=0.006, t 
test) (Figure 6a). In the radial arteries the difference in number of adventitial vessels failed to 
reach statistical significance (Ad.VEGF-A165: 26.4±19.2, n=28 arteries from 8 animals, 
Ad.LacZ: 16.4±13.5, n=20 arteries from 6 animals, p=0.051, t test). The number of vessels 
per mm
2
 of adventitial tissue was lower in radial arteries compared to the uterine arteries 
(Figure 6b). 
The restricted diet had a significant effect on both proliferation and apoptosis in the placenta. 
Proliferation was reduced in Ad.LacZ (19.8±20.4 cells/field of view, n=5 placentas from 5 
dams) and Ad.VEGF-A165 treated animals (37.3±34.2, n=4 placentas from 4 animals) 
compared to ad lib animals (70.1±25.0, n=6 placentas from 3 dams), as measured by positive 
Ki-67 staining (p=0.001, Mann Whitney U test) (Figure 6c). Similarly, apoptosis was reduced 
in Ad.LacZ (90.7±128.5 cells/field of view, n=5 placentas from 5 dams) nutrient restricted 
animals compared to ad lib animals (342.8±45.4, n=6 placentas from 3 dams), as measured 
by positive cleaved caspase-3 staining (p=0.001, Mann Whitney U test) (Figure 6d).  
Following Ad.VEGF-A165 treatment however, there was a significant increase in the number 
of cleaved caspase-3 stained cells (287±114.8, n=4 placentas from 4 animals, p=0.025, Mann 
Whitney U test), such that there was no difference between ad lib and Ad.VEGF-A165 treated 





























































































































































































































































































































































































In this study we provide further evidence, in a guinea pig model of fetal growth restriction 
that mid-gestation maternal gene therapy giving transient local over-expression of VEGF in 
the uteroplacental circulation improves fetal growth rate and fetal weight at term. We 
compared the results of animals treated with Ad.VEGF-A165 Ad.LacZ vector with two 
contemporaneous groups of (1) normally fed non-FGR guinea pigs and (2) untreated maternal 
nutrient restricted FGR guinea pigs as reported previously (18). We confirmed short term 
VEGF expression in fetal and maternal blood and in transduced maternal uterine vessels 
without detectable vector transmission to the fetus. There was upregulation in eNOS and 
iNOS detected in transduced vessels, and enhanced vascular relaxation short term.  Guinea 
pigs have a haemomonochorial placentation, which is the most similar to human placentation 
in an animal model, with the exception of some non-human primates. In contrast to our work 
in sheep, this model is also closer to the human condition, in that the FGR is early rather than 
late onset, and therapy is applied mid-gestation at approximately the same stage as would be 
feasible in humans (therapy 29-39 gestational days, term 65 gestational days vs therapy 20-26 
weeks gestation, term 40 weeks gestation). Thus, experimental results obtained from pregnant 
guinea pigs are likely to hold great relevance for clinical translation. 
 
Although the mean weight increase is a modest 3%, there was nevertheless a significant 
improvement in fetal growth rate in fetuses receiving Ad.VEGF-A165. Even for normally 
grown fetuses born very premature, small increases in fetal growth and gestation at birth are 
associated with major improvements in survival and morbidity (3,4). Therapeutic 
interventions for severe fetal growth restriction might therefore be successful by improving 
outcome if they lead to even small increases in fetal growth, or later gestation at delivery. 
Several other fetal measurements were significantly increased in response to Ad.VEGF-A165 






















































































































































































































































































































































































gene therapy, with treated fetuses having an increased crown rump length, brain and liver 
weight, although no change in the abdominal circumference was detected. This is in contrast 
to ultrasound measurement findings from our previous research in sheep (14) and from other 
groups studying the FGR mouse (22). Placental weight, diameter and area were not affected 
by Ad.VEGF-A165 treatment, with only placental depth being increased. The gain in fetal 
weight did not appear therefore to be mediated through an increase in placental dimensions.  
 
Delivery of Ad.VEGF-A165 to the uterine and radial artery increased expression of VEGF 
shortly after vector delivery, showing efficient transduction of the vector, and high 
concentration of VEGF as detected in fetal blood serum, as well as a mild increase in 
maternal blood serum. We propose that released VEGF-A165 protein promoted an increase of 
eNOS and iNOS levels, via functional activation of VEGFR-2, potentially being the factor  
leading to angiogenesis and hypotension in the target vessels (24). We cannot speculate at 
this stage about the mechanism by which Ad.VEGF-A165 induces neovascularization in the 
uterine and radial artery system, as it will require further studies. Immunohistochemistry of 
the guinea pig uterine arteries (UtA) and radial arteries (RA) showed increased VEGF 
staining in Ad.VEGF-A165 treated animals, supporting the ELISA data. There was also 
positive staining for VEGR-1 and VEGFR-2, thus either or both of these receptor could have 
been involved in mediating the effects seen following Ad.VEGF-A165 treatment.   
 
Uterine arteries from Ad.VEGF-A165 treated dams demonstrated a greater relaxation in 
response to acetylcholine when examined in a myograph. This complements our previous 
work in the sheep, where the relaxation response in uterine arteries collected at short term 
time points was significantly increased in Ad.VEGF-A165-transduced vessels (11). Others 
have observed in vitro that VEGF-A165 is a powerful vasodilator of the fetoplacental 






















































































































































































































































































































































































vasculature (25), and adult vascular tone is regulated via VEGF-A induced vasodilation (26). 
ACh-induced relaxation of guinea-pig uterine artery is dependent on the release of nitric 
oxide (NO) from vascular endothelial cells (27).  
 
We also observed enhanced uterine artery vascularization via immunohistochemical staining 
of new blood vessels in the adventitia. In animal experiments, VEGF gene transfer is capable 
of inducing therapeutic angiogenesis in diverse tissues and organ systems. Overexpression of 
VEGF using viral vectors can stimulate significant neovascularization in skeletal muscles and 
myocardium (reviewed in (28)). Our own work has suggested that an increase in UBF is 
likely to be mediated in the longer term through neovascularisation within the perivascular 
adventitia (12,13).  
 
Safety will be an important consideration for translation into the clinic. Reassuringly there 
was no transgenic protein expression in any fetal tissues, as determined by RT-PCR. Only 
one maternal sample of non-target tissue tested positive, from an ovary sample, likely due to 
an inadvertent positioning of the gel/vector mixture proximal to the ovary during surgery.  
Pluronic gel has been used previously as a delivery vehicle for adenoviral vectors to the 
carotid artery of rats (29)(30)(31). We have demonstrated that external vascular application 
of Ad. vector combined with pluronic gel achieves very high levels of localized gene transfer 
and expression specifically at the site of administration in the uterine arteries in guinea pigs 
when compared to direct intravascular injection (19). The relatively smaller size of the 
uterine artery in guinea pigs compared to sheep limited the feasibility of intravascular 
injection. In pregnant women however, transfemoral uterine artery catheterization with 
temporary balloon occlusion of the vessel lumen could be used as a minimally invasive 
technique.  























































































































































































































































































































































































FGR in sheep and humans is associated with smaller placentas and reduced cellular 
proliferation (32)(33)(34).  We found similarly a significant reduction of proliferation in the 
placenta of the nutrient restricted guinea pigs. Treatment with Ad.VEGF-A165 did not affect 
the level of proliferation compared with Ad.LacZ-treated animals, as both remained lower 
than ad lib fed animals. FGR in the human is associated with increased placental apoptosis. 
In our study, however we found the opposite effect. Diet restricted animals treated with 
Ad.LacZ had significantly less apoptosis in the placenta than animals fed ad lib. However, 
treatment with Ad.VEGF-A165 restored apoptosis back to ad lib level. Whether this is a 
phenomenon confined to the guinea pig is unknown. It is unlikely to be a product of the Ad. 
treatment, as no evidence of vector was found in any placental samples.  
 
The degree of rescue of FGR seen in this study in nutrient restricted FGR guinea pigs did not 
appear to be as much as in our previous in sheep where FGR was created in the over-
nourished adolescent ewe (14, 35). There are differences in the animal models and 
experimental techniques that may explain this. The overnourished FGR sheep is a highly 
manipulated and controlled experimental model where exclusively singleton pregnancies 
with maximum genetic homogeneity are created by in vitro fertilization using eggs from 
superovulated donor ewes inseminated by a single sire with embryo transfer into adolescent 
ewes that are subsequently over fed. In contrast the nutrient restricted FGR guinea pig 
conceives over a 3-5 day period, carries between 1-5 pups, and is genetically heterogeneous 
(7, 18), resulting in a wider range of offspring weights and gestational ages than is found in 
the FGR sheep. The vector was applied externally to the uterine and radial arteries of the 
guinea pig circulation by necessity because of the small vessel size, using a thermolabile 
pluronic gel technique (19) rather than a direct uterine artery injection with stasis of blood 






















































































































































































































































































































































































flow used in the sheep study, which delivers the total dose concentrated to the vessel. In 
addition the vector dose was double in the sheep experiments: 1x10
10
vp per guinea pig 
(1x10
10
 per kg assuming a dam weight of 1kg), compared to 1x10
11 
vp per sheep (2x10
10
 per 
kg assuming a ewe weight of 50kg). To ensure the optimum gene transfer, in the clinical trial 
we plan to use an intravascular injection technique with doses comparable to those used in 
the sheep study. 
This study has confirmed that maternal gene therapy with Ad.VEGF-A165 is able to increase 
the fetal growth rate and term weight of fetuses in an animal model with placentation relevant 
to human FGR. Transduction with Ad.VEGF-A165 appears to achieve this outcome by 
increasing UtA vasorelaxation and promoting adventitial angiogenesis, with virtually no 
vector spread outside target tissues. Further work in this model to examine the long term 
effects of Ad.VEGF-A165 therapy in treated offspring will lend weight to applications for 
translation to the clinic. 
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Figures and tables legends 
  
























































































































































































































































































































































































a) Fetal weight and placental measurements: 






fetal weight 85.52 ± 13  88.01 ± 13.36* 0.028 
placental weight 5.33 ± 1.04 4.93 ± 0.18 0.220 
placental diameter 27.96 ± 2.54 26.92 ± 4.95 0.228 
placental depth 8.66 ± 1.83  8.96 ± 1.62** 0.001 
fetal/placental weight ratio 0.061±0.01 0.058±0.01 0.282 
b) Fetal size characteristics and fractional growth rate: 






lung weight (g) 1.62 ± 0.37  1.73 ± 0.29** 0.002 
liver weight (g) 4.38 ± 1.41 4.76 ± 1.41* 0.027 
kidney weight (g) 0.43 ± 0.12 0.40 ± 0.09 0.205 
heart weight (g) 0.49 ± 0.12 0.49 ± 0.06 0.413 
brain weight (g) 2.24 ± 0.35  2.48 ± 0.18* 0.039 
biparietal diameter (BPD) (mm) 20.03 ± 1.18 20.30 ± 1.54 0.348 
BPD fractional growth rate (mm/day) 0.309 ± 0.093 0.32 ± 0.081** 0.008 
crown rump length (CRL) (mm) 108.92 ± 8.62  113.61 ± 7.26* 0.020 
occipital snout length (OSL) (mm) 40.18 ± 4.63  43.2 ± 2.20* 0.033 
OSL fractional growth rate (mm/day) 0.863 ± 0.166 0.88 ± 0.081* 0.040 
abdominal circumference (AC) (mm) 94.82 ± 5.67 94.71 ± 6.60 0.991 
brain/fetal weight ratio 0.026 ± 0.004  0.029 ± 0.005* 0.036 
 
Table 1: Fetal weight and placental measurements of FGR pregnancies following mid-
gestation treatment with Ad.LacZ or Ad.VEGF-A165 (a); Fetal size characteristics and 
fractional growth rate in pregnancies affected by FGR following mid-gestation maternal 
uterine artery treatment with Ad.LacZ or Ad.VEGF-A165 (b). 
a
n=19 pups from 7 dams;  
b
n=26 
pups from 8 dams. All data are means ± standard deviation. Data were analysed by 
Generalized Linear Mixed Models. Significant difference between treatment groups, * 
P<0.05, ** P<0.01 















































































































































































































































































































































































































































































































































































































































































































































































Figure 1: Fetal weight and placental measurements of FGR pregnancies following mid-
gestation treatment with Ad.LacZ (n=19 pups from 7 dams) or Ad.VEGF-A165 (n=26 pups 
from 8 dams). All data are means ± standard deviation. Data were analysed by Generalized 
Linear Mixed Models. Significant difference between treatment groups, * P<0.05, ** P<0.01.  
  
























































































































































































































































































































































































Figure 2: ELISA measurement of VEGF-A in the serum (a), uterine arteries (b), and radial 
arteries (c) following treatment with Ad.LacZ or Ad.VEGF-A165. Samples were collected 3-8 
days following vector application. 
  
























































































































































































































































































































































































Figure 3: Immunohistochemistry for localisation of expression of VEGF (a, d), VEGFR1 (b, 
e) and VEGFR2, (c, f) in the uterine arteries following gene therapy with Ad.LacZ or 
Ad.VEGF-A165. Samples were collected 3-8 days following adenoviral transduction. 
  
























































































































































































































































































































































































Figure 4: RT-PCR to examine vector spread.  (a) A semi-nested reverse transcription (RT)-
PCR with primers specific for Ad.VEGF-A165 in guinea pig maternal and fetal samples was 
positive in the Ad.VEGF-A165-transduced uterine and radial arteries, but negative in other 
tissues. (b) RT-PCR with primers specific for the β-actin gene is positive in all guinea pig 
samples. Lane 1, no template control; 2, positive control of human umbilical vein endothelial 
cells infected in vitro with Ad.VEGF-A165; 3, uterine artery; 4, radial artery; 5, maternal 
heart; 6, maternal lung; 7, placenta; 8, umbilical cord; 9, fetal heart; 10, fetal lung; 11, fetal 
gonad. A 1kb DNA ladder was used for sizing. 
  
























































































































































































































































































































































































Figure 5: Vascular reactivity of uterine arteries 3-8 days after vector administration, 
measured by wire myography. (a) Logarithmic dose-response curve to L-phenylephrine (PE). 
The contractility of the vessel is expressed as a percentage of the response to KCl. (b) 
Logarithmic dose-response curve to acetylcholine (ACh). The relaxation is expressed as a 
percentage of inhibition of PE-induced contractions. Error bars denote standard deviation. 
*Relaxation p<0.05, tension non-significant. 
  
























































































































































































































































































































































































Figure 6: Immunohistochemistry analysis of endothelial cell proliferation and placental 
turnover.  Von Willebrand Factor staining for vessels in the adventitia of uterine (a) and 
radial (b) arteries showed an increase in neovascularisation around uterine, but not radial, 
arteries in Ad.VEGF-A165-treated animals. Diet restriction reduced both proliferation (c) and 
apoptosis (d) in the placenta. Ad.VEGF-A165 treatment partially restored apoptosis. Error bars 
denote standard deviation. 
  























































































































































































































































































































































































Supplementary Table 1 
Guinea Pig dams included in the study (n=15) 
Number of dams Treatment Pups generated 
7 Ad.LacZ 19 
8 Ad.VEGF-A165 26 
 
Guinea Pig dams excluded from the study due to surgical complications (n=10) 
Number of dams Reason for exclusion 
4 Miscarriage at 1, 5, and 6 days post-surgery 
2 Leg wound during operative handling, culled 
1 Aspiration pneumonia 
1 Abdominal infection 
1 Sign of distress and weight loss post-operation, culled 




Supplementary Table 1: Detailed report on number of Guinea Pig dams included (a) and 
excluded from the study (b), with details that determined their exclusion. 
  
























































































































































































































































































































































































Supplementary Figure 1: Representative Western blot for eNOS/iNOS (1 of 3 performed, 
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